Skip to main content
Top
Published in: The Patient - Patient-Centered Outcomes Research 3/2008

01-07-2008 | Original Research Article

Hormonal Contraceptive Users’ Self-Reported Benefits, Adverse Reactions, and Fears in 2001 and 2007

Authors: Miia Tiihonen, Hanna-Mari Leppänen, Anna-Mari Heikkinen, Riitta Ahonen

Published in: The Patient - Patient-Centered Outcomes Research | Issue 3/2008

Login to get access

Abstract

Background: Hormonal contraceptives (HCs) are the most common contraceptive method in western countries. The fears and problems experienced by users of HCs can have an impact on their quality of life, and lead to abortions and unwanted pregnancies.
Objective: To investigate whether experiences and perceptions of HC users in Finland have changed from 2001 to 2007.
Methods: Data were collected using questionnaire surveys of women using HCs in 2001 and 2007. In Finland, HCs are available with a physician’s prescription, and are only supplied in community and university pharmacies. University pharmacies in 12 large cities across Finland were selected to distribute the questionnaires. The response rate was 53% (n = 264) in 2001 and 55% (n = 436) in 2007. The average age of the respondents was 26 years in both surveys. The surveys measured self-reported benefits and adverse reactions, preconceptions, fears, knowledge, and opinions.
Results: The number of HC users reporting fears increased from 2001 to 2007 (p = 0.002), whereas the number of HC users reporting adverse reactions decreased (p = 0.013). In both surveys, the most common fear was infertility after HC use (17% vs 26% for 2001 and 2007, respectively). In both surveys, the most common benefits were efficacy and regular menstrual cycle, and the most common adverse reactions were mood swings, lowered libido, and weight gain.
Conclusions: Our study suggests that, although women using HCs were convinced about their benefits, and the number of users reporting adverse reactions had decreased from 2001 to 2007, the number of users reporting fears had increased. Healthcare professionals need to provide counseling in order to alleviate women’s fears and to correct false perceptions of HCs.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
2.
go back to reference Kosunen EA, Sihvo S, Nikula M, et al. Birth control. In: Koponen P, Luoto R, editors. Reproductive health in Finland: the Health 2000 survey. B/2004 ed. Helsinki: National Public Health Institute, 2004 Kosunen EA, Sihvo S, Nikula M, et al. Birth control. In: Koponen P, Luoto R, editors. Reproductive health in Finland: the Health 2000 survey. B/2004 ed. Helsinki: National Public Health Institute, 2004
5.
go back to reference Jones RK, Darroch JE, Henshaw SK. Contraceptive use among US women having abortions in 2000–2001. Perspect Sex Reprod Health 2002; 34(6): 294–303PubMedCrossRef Jones RK, Darroch JE, Henshaw SK. Contraceptive use among US women having abortions in 2000–2001. Perspect Sex Reprod Health 2002; 34(6): 294–303PubMedCrossRef
6.
go back to reference Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–8PubMedCrossRef Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception 1995; 51: 283–8PubMedCrossRef
7.
go back to reference Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007; 196: 412e1–e7CrossRef Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007; 196: 412e1–e7CrossRef
8.
go back to reference Tiihonen MJ, Heikkinen A-M, Ahonen RS. Do Finnish women using hormone replacement therapy need more information about risks. Pharm World Sci 2007; 29(6): 635–40PubMedCrossRef Tiihonen MJ, Heikkinen A-M, Ahonen RS. Do Finnish women using hormone replacement therapy need more information about risks. Pharm World Sci 2007; 29(6): 635–40PubMedCrossRef
9.
go back to reference National Agency for Medicines and Social Insurance Institution. The Finnish statistics of medicine 2005. Helsinki: Edita Prima Oy, 2006 National Agency for Medicines and Social Insurance Institution. The Finnish statistics of medicine 2005. Helsinki: Edita Prima Oy, 2006
10.
go back to reference Sihvo S, Ahonen R, Mikander H, et al. Self-medication with vaginal antifungal drugs: physicians’ experiences and women’s utilization patterns. Fam Pract 2000 Apr; 17(2): 145–9PubMedCrossRef Sihvo S, Ahonen R, Mikander H, et al. Self-medication with vaginal antifungal drugs: physicians’ experiences and women’s utilization patterns. Fam Pract 2000 Apr; 17(2): 145–9PubMedCrossRef
12.
go back to reference Farrow A, Hull MG, Northstone K, et al. Prolonged use of oral contraception before planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002 Oct 17; 10: 2754–61CrossRef Farrow A, Hull MG, Northstone K, et al. Prolonged use of oral contraception before planned pregnancy is associated with a decreased risk of delayed conception. Hum Reprod 2002 Oct 17; 10: 2754–61CrossRef
13.
go back to reference Murphy P, Kirkman A, Hale RW. A national survey of women’s attitudes toward oral contraception and other forms of birth control. Womens Health Issues 1995; 5(2): 94–9PubMedCrossRef Murphy P, Kirkman A, Hale RW. A national survey of women’s attitudes toward oral contraception and other forms of birth control. Womens Health Issues 1995; 5(2): 94–9PubMedCrossRef
14.
go back to reference Gilliam ML, Tapia B, Warden M, et al. Concerns about contraceptive side effects among young Latinas: a focus-group approach. Contraception 2004; 70(4): 299–305PubMedCrossRef Gilliam ML, Tapia B, Warden M, et al. Concerns about contraceptive side effects among young Latinas: a focus-group approach. Contraception 2004; 70(4): 299–305PubMedCrossRef
15.
go back to reference Gallo MF, Grimes DA, Schulz KF, et al. Combination estrogenprogestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004 Feb; 103(2): 359–73PubMedCrossRef Gallo MF, Grimes DA, Schulz KF, et al. Combination estrogenprogestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet Gynecol 2004 Feb; 103(2): 359–73PubMedCrossRef
16.
go back to reference Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998 Mar–Apr; 30(2): 89–92PubMedCrossRef Rosenberg MJ, Waugh MS, Burnhill MS. Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation. Fam Plann Perspect 1998 Mar–Apr; 30(2): 89–92PubMedCrossRef
17.
go back to reference Oddens BJ. Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 1999 May; 59(5): 277–86PubMedCrossRef Oddens BJ. Women’s satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 1999 May; 59(5): 277–86PubMedCrossRef
18.
go back to reference Sihvo S, Hemminki E. Self-medication of dyspepsia: how appropriate is it? Scand J Gastroenterol 1997 Sep; 32(9): 855–61PubMedCrossRef Sihvo S, Hemminki E. Self-medication of dyspepsia: how appropriate is it? Scand J Gastroenterol 1997 Sep; 32(9): 855–61PubMedCrossRef
19.
go back to reference Vainio K. Developing patient counselling in Finnish community pharmacies. Kuopio: Kuopio University Publications A. Pharmaceutical Sciences 78, 2004 Vainio K. Developing patient counselling in Finnish community pharmacies. Kuopio: Kuopio University Publications A. Pharmaceutical Sciences 78, 2004
Metadata
Title
Hormonal Contraceptive Users’ Self-Reported Benefits, Adverse Reactions, and Fears in 2001 and 2007
Authors
Miia Tiihonen
Hanna-Mari Leppänen
Anna-Mari Heikkinen
Riitta Ahonen
Publication date
01-07-2008
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 3/2008
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.2165/1312067-200801030-00004

Other articles of this Issue 3/2008

The Patient - Patient-Centered Outcomes Research 3/2008 Go to the issue

Original Research Article

The Burden of Restless Legs Syndrome

Pioneer Profile

Erik Rifkin, PhD

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine